Overview

An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.

Status:
Recruiting

Trial end date:
2023-12-18

Target enrollment:

Participant gender:

Summary

This randomized phase 1b/2 open-label study will evaluate the efficacy of etrumadenant (AB928) treatment combinations in patients with metastatic colorectal cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Arcus Biosciences, Inc.

Treatments:

Bevacizumab